The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
Ashleigh S Davey, Matthew E Call, Melissa J Call
Cancers | MDPI | Published : 2021
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B cell malignancies, improving patient survival and long-term remission. Nonetheless, over 50% of patients experience severe treatment-related toxicities including cytokine release syndrome (CRS) and neurotoxicity. Differences in severity of toxic side-effects among anti-CD19 CARs suggest that the choice of costimulatory domain makes a significant contribution to toxicity, but comparisons are complicated by additional differences in the hinge and transmembrane (TM) domains of the most commonly used CARs in the clinic, segments that have long been considered to perform purely structural roles. In this perspective,..View full abstract
Awarded by NHMRC
We acknowledge NHMRC project grant 1158249 for funding and article processing charges.